Downstream Manufacturing Webinars
-
Industry-Leading Lentiviral Titers Through Optimized Production Technology
8/28/2023
See how VirusExpress' technology was optimized to provide industry-leading lentiviral titer and a streamlined approach to accelerate development timelines and de-risk manufacturing.
-
Characterizing AAV Encapsidated Nucleic Acid Sequences Using NGS
8/11/2023
Here, we discuss the characterization of several representative AAV molecules using next-generation sequencing (NGS), including the sequencing process, bioinformatic analysis, and representative results.
-
Maximizing The Value Of Your AAV Using Small Volume AAV Testing
8/11/2023
Learn about MilliporeSigma's approach to method development, where more than one AAV critical quality attribute can be measured within a single analytical run.
-
Introducing New Technology To A Multi-Specific Antibody Line
8/9/2023
Bayer Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses audience questions on introducing new purification technologies and multi-column chromatography to multi-specific mAb processing environments in this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline.
-
Challenges To Developing High Concentration Formulation For Multi-Specific Antibodies
8/9/2023
During the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline, Bayer’s Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., answered audience questions on overcoming challenges in high-concentration antibody formulations, while simultaneously maintaining purity.
-
PAT In Multi-Specific Antibody Manufacturing
8/9/2023
During the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline, Bayer’s Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., offered advice on the role of process analytical technologies and continuous processes in multi-specific antibody production, with a focus on achieving steady-state conditions.
-
Purification Strategies For New Classes Of Antibodies
8/9/2023
In this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline, Bayer’s Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses an audience question concerning purification strategies in the growing multi-specific antibody field.
-
Maintaining Downstream Quality In Multi-Specific Antibody Manufacturing
8/9/2023
Bayer Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses audience questions on downstream multi-specific mAb processing challenges, specifically purification in terms of CPP and QRA, and microbial or thermal degradation, in this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline.
-
Multi-Specific Antibody Development: What Challenges The Need For Speed?
8/9/2023
In this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline, Bayer’s Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses why the industry is pursuing faster, more cost-effective multi-specific antibody development and some of the major challenges standing in the way of efficiency.
-
Data Integrity And Compliance In Bioanalysis
8/8/2023
Learn how a combination of controlled compliant workflow execution, dramatically streamlined data acquisition and an “audit by exception” approach offers the next phase of innovation within bioanalysis.